TAGLN2 and neoplasm: This study demonstrated that TAGLN2 expression is upregulated in the early stages of gastric cancer and increases with tumor progression, and suggested the involvement of dual regulatory pathways in upregulating resistance signature ISGs, with cytosolic ssDNA aggregation playing a crucial intermediary role.